Investigating causes of diplopia to minimise morbidity and mortality

News
Article

Canadian investigators urged quick neuro-ophthalmologic referrals to limit the progress of life- and vision-threatening conditions

A red light with an alarm symbol. It reads "SOS." Concept image for emergency, medical emergency, neurology and ophthalmology referral. Image credit: ©Nicole Kwiatkowski – stock.adobe.com

Investigators said it is crucial for clinicians to understand the common causes of diplopia and a system to differentiate between urgent and nonurgent cases. Image credit: ©Nicole Kwiatkowski – stock.adobe.com

A new study emphasised that patients who present with diplopia should be referred expeditiously for appropriate care and treatment to reduce morbidity and mortality. Mariam Issa, MD, and colleagues emphasised the importance of urgent neuro-ophthalmologic referral for patients with diplopia to allow for appropriate evaluation and investigations.1 She is from the Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada.

Diplopia can result from a number of different causes ranging from refractive errors, which are benign, to life-threatening emergencies, such as aneurysmal compression of cranial nerves,2 the investigators explained.

“It is important for clinicians first encountering a patient with diplopia to understand its common causes and to have an approach for these patients to differentiate between urgent and nonurgent cases. Although it was previously found that 16% of patients presenting with diplopia to an emergency department have a life-threatening condition,3 little is known about the prevalence of systemic and ocular adverse effects specifically in patients referred for neuro-ophthalmic evaluation with the chief complaint of diplopia,” Issa and her colleagues said.

They explained the difference between this and previous studies that focused on diplopia. They said, “No comprehensive study exists on the aetiologic classification, clinical features and assessment of morbidity/mortality of all patients referred for the evaluation of diplopia to a tertiary neuro-ophthalmological practice where referrals are received from other ophthalmologists, neurologists, general practitioners and optometrists. Patients seen in this setting are unique in that not only do they experience a variety of diplopia aetiologies but also have a previous record of being seen by other practitioners. Therefore, this study offers the opportunity to ascertain the potential for morbidity and mortality (potential for loss of vision, progression of symptoms or systemic morbidity or mortality) in patients referred for evaluation of diplopia based on their final diagnosis,” they emphasised.

Retrospective chart review

The researchers reviewed the charts of patients seen by tertiary neuro-ophthalmologists in a tertiary neuro-ophthalmology practice between 2 December, 2021, and 21 May, 2022. Their study included all patients who had been referred due to the complaint of diplopia.

The primary study outcome was the potential for vision loss, symptom progression or systemic morbidity or mortality in patients who had not been referred to a neuro-ophthalmologist.

A total of 196 patients (48.5% women; mean age, 61 years) were identified who had been referred for diplopia.

“The most common final diagnosis reached following neuro-ophthalmology consultation were cranial nerve palsies (38.3%, 75 of 196), convergence insufficiency and decompensated phoria (22.4%, 44 of 196), non-neuro-ophthalmic causes (19.9%, 39 of 196), thyroid eye disease (4.5%, 9 of 196), myasthenia gravis (3.5%, 7 of 196) and multiple sclerosis (6 of 196, 3.1%). Based on the final diagnosis, 15.3% of patients referred to the neuro-ophthalmology service for diplopia had the potential for morbidity or mortality,” the investigators reported.

The morbidities to which they referred were visual loss resulting from severe papilloedema from untreated idiopathic intracranial hypertension in 1% (two of 196) and systemic morbidity or mortality in 3.0% (six of 196) from the final diagnosis, ie, brain aneurysms in two of 196, pituitary apoplexy in one of 196, anaplastic glioma in one of 196, and other malignancies in two of 196.

Other patients were diagnosed with thyroid eye disease (nine of 196), myasthenia gravis (seven of 196), and multiple sclerosis (six of 196), representing 11.2% (22 of 196) of the study population.

Of the patients who had a pre-referral neuroimaging study, 30.1% required additional neuroimaging after neuro-ophthalmic consultation.

Dr Issa and colleagues concluded that “17.1% of all new patients seen at a tertiary neuro-ophthalmological practice were primarily referred for the evaluation of diplopia, and 15% of all patients referred for diplopia harboured the potential for morbidity and mortality without correct diagnosis and management. As diplopia can be caused by life- and vision-threatening aetiologies, the low accuracy of prereferral diagnosis and neuroimaging found in this study emphasised the importance of urgent neuro-ophthalmologic referral. It is important for clinicians to have an appropriate approach when encountering patients with diplopia to provide optimal care, prevent unnecessary investigations and initiate urgent referral to neuro-ophthalmology when necessary.”

References

  1. Issa M, Cioana M, Popovic MM, et al. Analysis of diplopia referrals in a tertiary neuro-ophthalmology center. Can J Ophthalmol. 2025; https://doi.org/10.1016/j.jcjo.2025.03.001
  2. Najem K, Margolin E. Diplopia. 2022; StatPearls.StatPearls Publishing, 2022 Accessed November 5, 2022; http://www.ncbi.nlm.nih.gov/books/NBK441905/
  3. De Lott LB, Kerber KA, Lee PP, Brown DL, Burke JF. Diplopia-related ambulatory and emergency department visits in the United States, 2003–2012. JAMA Ophthalmol. 2017;135:1339-1344.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.